Rani Therapeutics Holdings Stock Investor Sentiment

RANI Stock  USD 1.47  0.00  0.00%   
Under 54% of Rani Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding Rani Therapeutics Holdings suggests that many traders are impartial. Rani Therapeutics' investing sentiment shows overall attitude of investors towards Rani Therapeutics Holdings.
  

Rani Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Rani Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
six days ago at finance.yahoo.com         
RANI Impressive Bioavailability for RT-116
Yahoo News
over a week ago at finance.yahoo.com         
Rani Therapeutics Holdings, Inc.s largest shareholders are individual investors who were rewarded as...
Yahoo News
over a week ago at news.google.com         
Rani Therapeutics Holdings, Inc.s largest shareholders are individual investors who were rewarded as...
Google News at Macroaxis
over a week ago at www.macroaxis.com         
Disposition of 83724 shares by Svai Sanford of Rani Therapeutics at 9.44 subject to Rule 16b-3
Macroaxis News
over a week ago at news.google.com         
Rani Therapeutics Given Buy Rating at HC Wainwright - MarketBeat
Google News at Macroaxis
over two weeks ago at simplywall.st         
Is Rani Therapeutics Holdings Using Too Much Debt?
Simply Wall St News at Macroaxis
over two weeks ago at gurufocus.com         
Rani Therapeutics Announces Preclinical Data Demonstrating Succe
Gurufocus Stories at Macroaxis
over a month ago at news.google.com         
Rani Therapeutics Holdings, Inc. Receives 11.71 Average Target Price from Brokerages - MarketBeat
Google News at Macroaxis
over a month ago at news.google.com         
Rani Therapeutics stock hits 52-week low at 1.29 - Investing.com
Google News at Macroaxis
over two months ago at news.google.com         
Rani Therapeutics Holdings, Inc. Receives Average Rating of Buy from Analysts - MarketBeat
Google News at Macroaxis
over two months ago at news.google.com         
Rani Therapeutics stock hits 52-week low at 1.32 - Investing.com
Google News at Macroaxis
over two months ago at gurufocus.com         
Insider Buying Kate Mckinley Acquires Shares in Rani Therapeutics Holdings Inc
Gurufocus Stories at Macroaxis
over two months ago at www.macroaxis.com         
Disposition of 15423 shares by Nanavaty Maulik of Rani Therapeutics at 2.84 subject to Rule 16b-3
Macroaxis News
over two months ago at www.macroaxis.com         
Acquisition by Mckinley Kate of 17960 shares of Rani Therapeutics at 1.67 subject to Rule 16b-3
Macroaxis News
over two months ago at gurufocus.com         
CEO Talat Imran Acquires Additional Shares of Rani Therapeutics Holdings Inc
Gurufocus Stories at Macroaxis
Far too much social signal, news, headlines, and media speculation about Rani Therapeutics that are available to investors today. That information is available publicly through Rani media outlets and privately through word of mouth or via Rani internal channels. However, regardless of the origin, that massive amount of Rani data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Rani Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Rani Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Rani Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Rani Therapeutics alpha.

Rani Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Talat Imran of 10296 shares of Rani Therapeutics at 1.94 subject to Rule 16b-3
12/09/2024
2
Acquisition by Mckinley Kate of 17960 shares of Rani Therapeutics at 1.67 subject to Rule 16b-3
12/13/2024
3
Disposition of 15423 shares by Nanavaty Maulik of Rani Therapeutics at 2.84 subject to Rule 16b-3
12/16/2024
4
Rani Therapeutics Holdings, Inc. Receives Average Rating of Buy from Analysts - MarketBeat
12/20/2024
5
Rani Therapeutics Announces Preclinical Data Demonstrating Succe
02/05/2025
6
Disposition of 83724 shares by Svai Sanford of Rani Therapeutics at 9.44 subject to Rule 16b-3
02/14/2025
7
RANI Impressive Bioavailability for RT-116
02/18/2025

Complementary Tools for Rani Stock analysis

When running Rani Therapeutics' price analysis, check to measure Rani Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rani Therapeutics is operating at the current time. Most of Rani Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rani Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rani Therapeutics' price. Additionally, you may evaluate how the addition of Rani Therapeutics to your portfolios can decrease your overall portfolio volatility.
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges